Reply

We thank Drs Giri and Sundaram for their letter and interest in our study. As you know, we have had a keen interest in this potential second clinical phenotype of esophageal adenocarcinoma (EAC) and agree that this subtype may need to be analyzed differently. However, it is also important to note that epidemiologic modeling suggests that this type of EAC likely starts with intestinal metaplasia.1 Furthermore, a molecular difference in the 2 EAC phenotypes has not yet yielded different molecular routes to cancer.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research